Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Research ArticleTheranostics

The Current State of Radiopharmaceutical Therapy

Chaitanya Divgi
Journal of Nuclear Medicine November 2018, 59 (11) 1706-1707; DOI: https://doi.org/10.2967/jnumed.118.214122
Chaitanya Divgi
Divgi Consulting LLC, Meadowbrook, Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

See the associated article on page 1708.

Many of us believe the roots of nuclear medicine are as much therapeutic as diagnostic. In a scenario mirroring the current theranostic paradigm, the first nuclear medicine radionuclide, 131I, was explored for its ability to interrogate the pathophysiologic features of thyroid disorders at about the same time as it was explored for its therapeutic utility.

131I therapy, however, remains both an art and a standardized procedure. Therapy with 131I—not only for hyperthyroidism but for thyroid cancer—varies across institutions, with consideration being paid to logistic issues and convenience in addition to possible adverse effects and efficacy (1). This variation may be a function of both the large therapeutic window and the relatively benign natural course of these diseases.

Increasing cost constraints and the consequent reluctance of institutional payers now necessitates greater rigor and standardization. Radiopharmaceutical therapy in cancer needs approval in a manner comparable to that for any other oncologic therapy, with hard measures of efficacy and strict regimens of therapy that specify radioactivity amounts and administration schedules.

Randomized phase III trials are thus perhaps a prerequisite for Food and Drug Administration approval. Approval of 153Sm-ethylenediamine tetra(methylene phosphonic acid) (153Sm-lexidronam [Quadramet; Lantheus]) and 223Ra-dichloride (Xofigo; Bayer) followed rigorous demonstration of subjective (pain control) and objective (survival) improvement, respectively, compared with a statistically meaningful control population (2,3).

Comparable rigor in the therapy trial of gastroenteropancreatic neuroendocrine tumors using a 177Lu-labeled peptide (177Lu-DOTATATE [Lutathera; Advanced Accelerator Applications]) targeting a somatostatin receptor subtype (4) resulted in priority review of the agent by the Food and Drug Administration. The Food and Drug Administration was responsive to health-care needs and facilitated an expanded-access program to gather more efficacy data that enabled agent approval (5).

For several decades, neuroendocrine tumors that overexpress norepinephrine transporter have been treated with 131I labeled to a norepinephrine analog, benzylguanidine. The resultant compound—131I-meta-iodo-benzylguanidine (or 131I-MIBG)—has been used outside the United States, much like radioiodine therapy, in a schedule determined both by efficacy and by logistics (6). Efforts to enhance the availability and use of this therapy were perhaps inevitable given its demonstrated efficacy in a theranostic setting, exemplified by imaging to confirm biodistribution and tumor targeting followed by therapy with a large amount of radioactivity. Edward Coleman at Duke University led the systematic evaluation of 131I-MIBG therapy in adult NET (7), and an article by Kane et al. in this issue of The Journal of Nuclear Medicine (8) continues that fine tradition.

The retrospective review by Kane et al. demonstrated significant symptom relief and survival benefit in 211 patients treated with 131I-MIBG for metastatic neuroendocrine tumors at Duke University Hospital from 1991 to 2014 (8). The review confirms what the community has known for quite a while: 131I-MIBG therapy results in symptom improvement, and a delay in tumor growth, in a substantial proportion of treated patients. (Improvement over existing therapy could only be suggested in this retrospective review without a matched control.)

The article also points out the need for continuing rigor in the clinical testing of all radiopharmaceutical therapies: “In particular, future studies would benefit from more consistent documentation of performance status in the clinical record, as well as the use of some objective index of general wellness to separate the influence of multiple therapies independent of the propensity to survive.” There are several such indices, and their application is routine in most oncology practice (9).

The authors end their Discussion by pointing out the weaknesses—largely involving missing data regarding patient status—that preclude greater confidence in the conclusions of their study. That experience should act as a cautionary tale that guides our clinical conduct; we need to adopt the highest oncology practice standards to evaluate our radiopharmaceutical therapies and enable them to be approved, accepted, and used as an integral option for an increasing number of diseases. We need to become as facile at recording patient performance scores and hematopoietic indices as we are at recording administered radioactivity amounts and absorbed doses.

Nuclear medicine incorporates chemistry, physics, biology, and instrumentation, among other broad fields of knowledge. Clinical nuclear medicine needs to incorporate other imaging as well as therapeutic modalities to optimize use of the manifold ways in which this exciting discipline affects health care, particularly in cancer. Our discipline is not a part of some other but rather is a whole that is greater than the sum of its myriad parts (themselves components of other specialties and scientific fields).

As nuclear medicine physicians, we have 2 broad clinical responsibilities. We evaluate images of in vivo radiopharmaceutical distribution to make clinical decisions, and we treat patients with therapeutic radiopharmaceuticals, bringing to bear our understanding of (molecular and clinical) radiochemistry, biology, and pathophysiology. Our unique molecular imaging capabilities need to be combined with morphologic imaging (conventional imaging) to provide insight into pathophysiologic processes; therefore, we need to be well versed in all aspects of in vivo imaging. Only thus are we able to gain the confidence of referring clinician and patient alike.

We must similarly be well versed in all aspects of radiopharmaceutical therapy, not just those that relate to radiation safety and toxicity. We need to take care of our patients, not only administering the radiopharmaceutical but also considering ways to ameliorate toxicity or enhance efficacy with other treatment modalities. We need to work closely with our patients as well as with our clinical colleagues. We need to be clinicians, expert in all aspects of patient care and rigorously attending to clinical practice and management. The only way we can optimize use of our therapeutic arsenal is by becoming accepted as clinicians by our clinical colleagues.

DISCLOSURE

No potential conflict of interest relevant to this article was reported.

Footnotes

  • Published online Jun. 29, 2018.

  • © 2018 by the Society of Nuclear Medicine and Molecular Imaging.

REFERENCES

  1. 1.↵
    1. Silberstein EB,
    2. Alavi A,
    3. Balon HR,
    4. et al
    . The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med. 2012;53:1633–1651.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Serafini AN,
    2. Houston SJ,
    3. Resche I,
    4. et al
    . Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998;16:1574–1581.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Parker C,
    2. Nilsson S,
    3. Heinrich D,
    4. et al
    .; ALSYMPCA investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–223.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Strosberg J,
    2. El-Haddad G,
    3. Wolin E,
    4. et al
    .; NETTER-1 trial investigators. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–135.
    OpenUrlCrossRef
  5. 5.↵
    FDA approves new treatment for certain digestive tract cancers. U.S. Food and Drug Administration website. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm594043.htm. Published January 26, 2018. Accessed August 2, 2018.
  6. 6.↵
    1. Giammarile F,
    2. Chiti A,
    3. Lassmann M,
    4. et al
    . EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging. 2008;35:1039–1047.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Coleman RE,
    2. Stubbs JB,
    3. Barrett JA,
    4. de la Guardia M,
    5. Lafrance N,
    6. Babich JW
    . Radiation dosimetry, pharmacokinetics, and safety of ultratrace iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid. Cancer Biother Radiopharm. 2009;24:469–475.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Kane A,
    2. Thorpe MP,
    3. Morse MA,
    4. et al
    . Predictors of survival in 211 patients with stage IV pulmonary and gastroenteropancreatic MIBG-positive neuroendocrine tumors treated with 131I-MIBG. J Nucl Med. 2018;59:1708–1713.
    OpenUrl
  9. 9.↵
    1. Oken MM,
    2. Creech RH,
    3. Tormey DC,
    4. et al
    . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–655.
    OpenUrlCrossRefPubMed
  • Received for publication June 11, 2018.
  • Accepted for publication June 23, 2018.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 59 (11)
Journal of Nuclear Medicine
Vol. 59, Issue 11
November 1, 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Current State of Radiopharmaceutical Therapy
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
The Current State of Radiopharmaceutical Therapy
Chaitanya Divgi
Journal of Nuclear Medicine Nov 2018, 59 (11) 1706-1707; DOI: 10.2967/jnumed.118.214122

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The Current State of Radiopharmaceutical Therapy
Chaitanya Divgi
Journal of Nuclear Medicine Nov 2018, 59 (11) 1706-1707; DOI: 10.2967/jnumed.118.214122
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

  • Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG
  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Theranostics

  • Efficacy and safety of 124I-mIBG dosimetry-guided high activity 131I-mIBG therapy of advanced pheochromocytoma or neuroblastoma
  • Prostate-Specific Membrane Antigen Expression on Positron Emission Tomography/Computed Tomography in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study
  • The prognostic role of 68Ga-PSMA11 PET-based response in prostate cancer patients undergoing taxane-based chemotherapy
Show more Theranostics

Clinical

  • Efficacy and safety of 124I-mIBG dosimetry-guided high activity 131I-mIBG therapy of advanced pheochromocytoma or neuroblastoma
  • Prostate-Specific Membrane Antigen Expression on Positron Emission Tomography/Computed Tomography in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study
  • The prognostic role of 68Ga-PSMA11 PET-based response in prostate cancer patients undergoing taxane-based chemotherapy
Show more Clinical

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire